Wolfgang Miesbach: How Safe Is AAV Gene Therapy?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Lindsey A George et al., published in Molecular Therapy, adding:
“6,000+ people treated. Nine tumors reported.
When a cancer shows up after AAV gene therapy, was the treatment to blame, or just chance?
That’s the new Opinion piece in Molecular Therapy by Lindsey George, Rebecca Ahrens-Nicklas and Frederic Bushman.
First, the reassuring part.
AAV gene therapy has a strong safety record. Across an estimated 6,000 plus people treated, only nine tumors have ever been reported afterward – and just one carries clear molecular proof that the vector itself caused the cancer.
That one case is sobering.
A child treated for MPS I at 13 months developed a brain tumor four years later.
The vector had landed inside a gene called PLAG1 and switched it on – using its own built-in regulatory elements to do it.
Encouragingly, the child remains neurologically intact.
The deeper lesson is about proof.
Vector DNA often inserts in a scrambled, rearranged mess, tumor tissue is scarce, and routine clinical labs simply don’t look for it.
In this case the team’s first four methods couldn’t reconstruct what had happened. It took long-read sequencing to finally map it.
Rare doesn’t mean impossible.
The authors make a strong case for rigor, transparency and long-term follow-up as these therapies reach more patients.”
Title: Evaluating cases of possible insertional mutagenesis after AAV gene therapy
Authors: Lindsey A George, Rebecca C Ahrens-Nicklas, Frederic D Bushman
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?